The global chronic gingivostomatitis treatment market size was valued at USD 13,500 million in 2021 and is projected to reach around USD 23,500 million in 2030 exhibiting a CAGR of 6.5% in the forecasted period. The growing incidences of gingivostomatitis instigated by herpes simplex virus (HSV) is predicted to boost the global chronic gingivostomatitis treatment market revenue growth. However, a deficiency of identification or diagnosis of chronic gingivostomatitis is among the major factor hindering revenue growth of the chronic gingivostomatitis treatment market.
Growing cases of gingivostomatitis produced by herpes simplex virus (HSV) is projected to drive the chronic gingivostomatitis treatment market. For example, according to the International Journal of Dentistry, an article published in October 2016, more than 90% of gingivostomatitis cases are initiated by herpes simplex virus (HSV) type 1, and the residue are caused by herpes simplex virus (HSV) type 2.
The beginning of COVID-19 has impacted financial status of numerous industry verticals across the global. The private healthcare sector is among the sectors, which has been significantly obstructed by the global pandemic. Furthermore, the pandemic has impacted growth of several businesses owing to safety measures instigated by many governments globally. The epidemic has affected the economy in three main ways, such as by creating disturbances in supply channels, by directly distressing production and demand, and through its monetary impact on healthcare markets around the world.
As a result, the pandemic is anticipated to obstruct the global chronic gingivostomatitis treatment market growth during the forecasted period.
Drug Class Insights
Based on the drug class, the global chronic gingivostomatitis treatment market is bifurcated into non-steroidal anti-inflammatory drugs, antiviral, antibacterial, and others. The non-steroidal anti-inflammatory drugs segment is anticipated to hold the largest share in the projected period. The factors affecting the market growth are increasing prevalence of chronic gingivostomatitis around the world. The efficient indication for the prevention and treatment of chronic gingivostomatitis.
Region Insights
Among regions, North America held the major share of the global market due to broad use of medicines and high expenditure on healthcare. Furthermore, fast adoption of new products in the U.S. boosts the chronic gingivostomatitis market in the region. Additionally, concentration of key healthcare corporations in the established nations of the region alongside a major market for oral hygiene products is fuelling the market in North America. Substantial expenditure by the U.S. on healthcare, holding 16% of GDP, additionally boosts the chronic gingivostomatitis treatment market in the region.
Europe is the second-largest market in the world due to high income and healthcare diffusion. Europe is controlled by nations such as Germany and France. The market in the U.K. is expected to increase at a fast pace. The huge influence of media and a growth in awareness about oral hygiene along with high per capita revenue of the population propels the chronic gingivostomatitis market in Europe.
Key Companies Insights
The market for chronic gingivostomatitis treatment is moderately competitive. With the rising applications of chronic gingivostomatitis treatment, new players are considering to enter the market. The companies are also involved in events like joint ventures, acquisitions, partnerships, mergers, and collaborations. These activities aid in growing the effect of the players in the chronic gingivostomatitis treatment market, ultimately boosting the market growth. Some of the key companies working in the global chronic gingivostomatitis treatment market include:
• Pfizer Inc.
• Taj Pharmaceutical limited.
• Ciron pharma
• Johnson & Johnson
• GlaxoSmithKline PLC
• Merck & CO., Inc.
• Novartis AG
• F. Hoffman La Roche AG
• Eli Lily and Company
• AstraZeneca Plc
• Other players
Some of the Recent Developments:
• In December 2020, Heritage Pharms offered ZOVIRAX (acyclovir), a suspension, a generic form of the GlaxoSmithKlines’ Zovirax.
Segments
By Drug Class
• Non-Steroidal Anti-Inflammatory Drugs
• Antiviral
• Antibacterial
• Others

By Treatment
• Physical Examination
• Biopsy
• Microbial Culture
• Others

By Distribution Channel
• Academic & Research
• Hospitals & Clinics
• Others
By Geography
• North America
o U.S.
o Canada
o Mexico
• Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Russia
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o ASEAN
• Latin America
o Brazil
o Argentina
o Colombia
• MEA
o South Africa
o Saudi Arabia
o UAE
o Egypt